Validity of the 6 minute walk test in facioscapulohumeral muscular dystrophy
© 2016 Wiley Periodicals, Inc..
INTRODUCTION: In preparation for future clinical trials, we determined the reliability, relationship to measures of disease severity, and consistency across sites of the 6 Minute Walk Test (6MWT) in patients with facioscapulohumeral muscular dystrophy (FSHD).
METHODS: Genetically defined and clinically affected FSHD participants at 2 sites performed the 6MWT, the Timed Up and Go, and the 30 foot Go/Timed 10 meter test as measures of mobility using standard procedures.
RESULTS: Eight-six participants representing the full range of severity performed the 6MWT. The mean 6MWT distance was 404.3 meters (SD 123.9), with no difference between sites. The 6MWT was reliable (n = 25; intraclass correlation coefficient = 0.99) and demonstrated moderate to strong correlations with lower extremity strength, functional outcomes, and FSHD Clinical Score.
CONCLUSIONS: The 6MWT is reliable and is associated with other measures of FSHD disease severity. Future directions include assessing its sensitivity to disease progression. Muscle Nerve 55: 333-337, 2017.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:55 |
|---|---|
| Enthalten in: |
Muscle & nerve - 55(2017), 3 vom: 15. März, Seite 333-337 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Eichinger, Katy [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 03.07.2017 Date Revised 16.03.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/mus.25251 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM262467992 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM262467992 | ||
| 003 | DE-627 | ||
| 005 | 20231224201816.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/mus.25251 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0874.xml |
| 035 | |a (DE-627)NLM262467992 | ||
| 035 | |a (NLM)27421252 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Eichinger, Katy |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Validity of the 6 minute walk test in facioscapulohumeral muscular dystrophy |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.07.2017 | ||
| 500 | |a Date Revised 16.03.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2016 Wiley Periodicals, Inc. | ||
| 520 | |a INTRODUCTION: In preparation for future clinical trials, we determined the reliability, relationship to measures of disease severity, and consistency across sites of the 6 Minute Walk Test (6MWT) in patients with facioscapulohumeral muscular dystrophy (FSHD) | ||
| 520 | |a METHODS: Genetically defined and clinically affected FSHD participants at 2 sites performed the 6MWT, the Timed Up and Go, and the 30 foot Go/Timed 10 meter test as measures of mobility using standard procedures | ||
| 520 | |a RESULTS: Eight-six participants representing the full range of severity performed the 6MWT. The mean 6MWT distance was 404.3 meters (SD 123.9), with no difference between sites. The 6MWT was reliable (n = 25; intraclass correlation coefficient = 0.99) and demonstrated moderate to strong correlations with lower extremity strength, functional outcomes, and FSHD Clinical Score | ||
| 520 | |a CONCLUSIONS: The 6MWT is reliable and is associated with other measures of FSHD disease severity. Future directions include assessing its sensitivity to disease progression. Muscle Nerve 55: 333-337, 2017 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a 6 Minute Walk Test | |
| 650 | 4 | |a clinical trials | |
| 650 | 4 | |a facioscapulohumeral muscular dystrophy | |
| 650 | 4 | |a neuromuscular disease | |
| 650 | 4 | |a outcome measures | |
| 700 | 1 | |a Heatwole, Chad |e verfasserin |4 aut | |
| 700 | 1 | |a Heininger, Susanne |e verfasserin |4 aut | |
| 700 | 1 | |a Stinson, Nikia |e verfasserin |4 aut | |
| 700 | 1 | |a Matichak Stock, Carly |e verfasserin |4 aut | |
| 700 | 1 | |a Grosmann, Carla |e verfasserin |4 aut | |
| 700 | 1 | |a Wagner, Kathryn R |e verfasserin |4 aut | |
| 700 | 1 | |a Tawil, Rabi |e verfasserin |4 aut | |
| 700 | 1 | |a Statland, Jeffrey M |e verfasserin |4 aut | |
| 700 | 0 | |a FSHD Clinical Trials Research Network |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Muscle & nerve |d 1985 |g 55(2017), 3 vom: 15. März, Seite 333-337 |w (DE-627)NLM000369063 |x 1097-4598 |7 nnns |
| 773 | 1 | 8 | |g volume:55 |g year:2017 |g number:3 |g day:15 |g month:03 |g pages:333-337 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/mus.25251 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 55 |j 2017 |e 3 |b 15 |c 03 |h 333-337 | ||